This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Prichard, M N Articles by Shipman, C Search for Related Content PubMed PubMed Citation Articles by Prichard, M N Articles by Shipman, C, Jr

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1993 March; 37(3): 540-545

Strategic design and three-dimensional analysis of antiviral drug combinations.

Department of Biologic and Materials Sciences, School of Dentistry, University of Michigan, Ann Arbor 48109.

ABSTRACT

The development of new drugs effective against human viral diseases has proven to be both difficult and time-consuming. Indeed, there are but 10 drugs licensed for such applications in the United States today. An attractive solution to this problem may be to optimize the efficacy and selectivity of existing antiviral drugs by combining them with agents that strategically block carefully selected metabolic pathways. This approach was used in the rational design of a three-drug combination to increase the apparent potency of acyclovir against herpes simplex virus. Recent advances in analytical techniques have made the evaluation of this complex drug strategy both possible and practical. A modified version of a previously described analytical method was used to identify optimal drug concentrations and to quantitate statistically significant synergy. Concentrations of 0.25 microM 5-fluorodeoxyuridine, 3.6 microM 2-acetylpyridine thiosemicarbazone, and 0.3 microM acyclovir were determined to be optimal in terms of antiviral activity. The volume of synergy produced was nearly 2,000 microM3% at a 95% level of confidence (corresponding to a 186-fold decrease in the apparent 50% inhibitory concentration of acyclovir with the addition of 0.25 microM 5-fluorodeoxyuridine and 3.6 microM 2-acetylpyridine thiosemicarbazone). We anticipate that this strategic approach and the supporting three-dimensional analytical method will prove valuable in designing and understanding multidrug therapies.

This article has been cited by other articles:

• Venkatesh, M. P., Rong, L. (2008). Human recombinant lactoferrin acts synergistically with antimicrobials commonly used in neonatal practice against coagulase-negative staphylococci and Candida albicans causing neonatal sepsis. J Med Microbiol 57: 1113-1121 [Abstract] [Full Text]  
• Nakata, H., Steinberg, S. M., Koh, Y., Maeda, K., Takaoka, Y., Tamamura, H., Fujii, N., Mitsuya, H. (2008). Potent Synergistic Anti-Human Immunodeficiency Virus (HIV) Effects Using Combinations of the CCR5 Inhibitor Aplaviroc with Other Anti-HIV Drugs. Antimicrob. Agents Chemother. 52: 2111-2119 [Abstract] [Full Text]  
• Li, Y., Sun, S., Guo, Q., Ma, L., Shi, C., Su, L., Li, H. (2008). In vitro interaction between azoles and cyclosporin A against clinical isolates of Candida albicans determined by the chequerboard method and time-kill curves. J Antimicrob Chemother 61: 577-585 [Abstract] [Full Text]  
• Sun, S., Li, Y., Guo, Q., Shi, C., Yu, J., Ma, L. (2008). In Vitro Interactions between Tacrolimus and Azoles against Candida albicans Determined by Different Methods. Antimicrob. Agents Chemother. 52: 409-417 [Abstract] [Full Text]  
• Gu, Z., Allard, B., de Muys, J. M., Lippens, J., Rando, R. F., Nguyen-Ba, N., Ren, C., McKenna, P., Taylor, D. L., Bethell, R. C. (2006). In Vitro Antiretroviral Activity and In Vitro Toxicity Profile of SPD754, a New Deoxycytidine Nucleoside Reverse Transcriptase Inhibitor for Treatment of Human Immunodeficiency Virus Infection. Antimicrob. Agents Chemother. 50: 625-631 [Abstract] [Full Text]  
• Howe, A. Y. M., Bloom, J., Baldick, C. J., Benetatos, C. A., Cheng, H., Christensen, J. S., Chunduru, S. K., Coburn, G. A., Feld, B., Gopalsamy, A., Gorczyca, W. P., Herrmann, S., Johann, S., Jiang, X., Kimberland, M. L., Krisnamurthy, G., Olson, M., Orlowski, M., Swanberg, S., Thompson, I., Thorn, M., Del Vecchio, A., Young, D. C., van Zeijl, M., Ellingboe, J. W., Upeslacis, J., Collett, M., Mansour, T. S., O'Connell, J. F. (2004). Novel Nonnucleoside Inhibitor of Hepatitis C Virus RNA-Dependent RNA Polymerase. Antimicrob. Agents Chemother. 48: 4813-4821 [Abstract] [Full Text]  
• Afeltra, J., Vitale, R. G., Mouton, J. W., Verweij, P. E. (2004). Potent Synergistic In Vitro Interaction between Nonantimicrobial Membrane-Active Compounds and Itraconazole against Clinical Isolates of Aspergillus fumigatus Resistant to Itraconazole. Antimicrob. Agents Chemother. 48: 1335-1343 [Abstract] [Full Text]  
• Odds, F. C. (2003). Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 52: 1-1 [Full Text]  
• Meletiadis, J., Mouton, J. W., Meis, J. F. G. M., Verweij, P. E. (2003). In Vitro Drug Interaction Modeling of Combinations of Azoles with Terbinafine against Clinical Scedosporium prolificans Isolates. Antimicrob. Agents Chemother. 47: 106-117 [Abstract] [Full Text]  
• Desbiolles, N., Piroth, L., Lequeu, C., Neuwirth, C., Portier, H., Chavanet, P. (2001). Fractional Maximal Effect Method for In Vitro Synergy between Amoxicillin and Ceftriaxone and between Vancomycin and Ceftriaxone against Enterococcus faecalis and Penicillin-Resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45: 3328-3333 [Abstract] [Full Text]  
• Lira, R., Contreras, L. M., Rita, R. M. S., Urbina, J. A. (2001). Mechanism of action of anti-proliferative lysophospholipid analogues against the protozoan parasite Trypanosoma cruzi: potentiation of in vitro activity by the sterol biosynthesis inhibitor ketoconazole. J Antimicrob Chemother 47: 537-546 [Abstract] [Full Text]  
• Robinson, B. S., Riccardi, K. A., Gong, Y.-f., Guo, Q., Stock, D. A., Blair, W. S., Terry, B. J., Deminie, C. A., Djang, F., Colonno, R. J., Lin, P.-f. (2000). BMS-232632, a Highly Potent Human Immunodeficiency Virus Protease Inhibitor That Can Be Used in Combination with Other Available Antiretroviral Agents. Antimicrob. Agents Chemother. 44: 2093-2099 [Abstract] [Full Text]  
• Bedard, J., May, S., L'Heureux, L., Stamminger, T., Copsey, A., Drach, J., Huffman, J., Chan, L., Jin, H., Rando, R. F. (2000). Antiviral Properties of a Series of 1,6-Naphthyridine and 7,8-Dihydroisoquinoline Derivatives Exhibiting Potent Activity against Human Cytomegalovirus. Antimicrob. Agents Chemother. 44: 929-937 [Abstract] [Full Text]  
• Drusano, G. L., D'Argenio, D. Z., Symonds, W., Bilello, P. A., McDowell, J., Sadler, B., Bye, A., Bilello, J. A. (1998). Nucleoside Analog 1592U89 and Human Immunodeficiency Virus Protease Inhibitor 141W94 Are Synergistic In Vitro. Antimicrob. Agents Chemother. 42: 2153-2159 [Abstract] [Full Text]  
• Maeda, K., Yoshimura, K., Shibayama, S., Habashita, H., Tada, H., Sagawa, K., Miyakawa, T., Aoki, M., Fukushima, D., Mitsuya, H. (2001). Novel Low Molecular Weight Spirodiketopiperazine Derivatives Potently Inhibit R5 HIV-1 Infection through Their Antagonistic Effects on CCR5. J. Biol. Chem. 276: 35194-35200 [Abstract] [Full Text]